Skip to content
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • FR
  • FR
×
Facebook-f Twitter Instagram Youtube Linkedin
Defeat Duchenne Canada
  • About Duchenne
    • Introduction
    • Duchenne Basics
      • What is Duchenne Muscular Dystrophy?
      • What Causes Duchenne Muscular Dystrophy?
        • The Role of Dystrophin
      • Genetics
        • Types of Mutations
        • Carriers
    • Diagnosis
      • Signs and Symptoms
      • Genetic and Diagnostic Testing
  • Living with Duchenne
    • Introduction
    • Duchenne Management
      • Phases of Duchenne
      • Emergency Care
      • Your Care Team
    • Canadian Neuromuscular Registry
    • Family Stories
    • Education & Support
      • Family Forums
      • Webinars
      • Canadians Talk Duchenne
      • Helpful Resources
    • Research & Clinical Trials
      • Areas of Duchenne Research
      • About Clinical Trials
        • Clinical Trial Finder Tool
      • Research We Fund
        • Our Impact in Research
  • Join the Fight
    • Introduction
    • Give a Gift
      • Hope Needs Help
      • Personal Giving
        • Donate Now
      • Legacy & Planned Giving
      • Corporate Giving
      • Your Gift in Action
    • Fundraise
    • Volunteer
      • Volunteer Opportunities
      • Volunteer Application
  • News & Events
    • News
    • Events
  • Our Impact
    • Introduction
    • Our Mission
    • Our History
    • Our Work
    • Our Families
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
    • Our Team
  • About Duchenne
    • Introduction
    • Duchenne Basics
      • What is Duchenne Muscular Dystrophy?
      • What Causes Duchenne Muscular Dystrophy?
        • The Role of Dystrophin
      • Genetics
        • Types of Mutations
        • Carriers
    • Diagnosis
      • Signs and Symptoms
      • Genetic and Diagnostic Testing
  • Living with Duchenne
    • Introduction
    • Duchenne Management
      • Phases of Duchenne
      • Emergency Care
      • Your Care Team
    • Canadian Neuromuscular Registry
    • Family Stories
    • Education & Support
      • Family Forums
      • Webinars
      • Canadians Talk Duchenne
      • Helpful Resources
    • Research & Clinical Trials
      • Areas of Duchenne Research
      • About Clinical Trials
        • Clinical Trial Finder Tool
      • Research We Fund
        • Our Impact in Research
  • Join the Fight
    • Introduction
    • Give a Gift
      • Hope Needs Help
      • Personal Giving
        • Donate Now
      • Legacy & Planned Giving
      • Corporate Giving
      • Your Gift in Action
    • Fundraise
    • Volunteer
      • Volunteer Opportunities
      • Volunteer Application
  • News & Events
    • News
    • Events
  • Our Impact
    • Introduction
    • Our Mission
    • Our History
    • Our Work
    • Our Families
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
    • Our Team
Donate Now
  • FR
  • FR
×

PepGen: Clearance by Health Canada of CTA for PGN-EDO51

Home
/
News & Events
/
News
/
Research & Development

PepGen: Clearance by Health Canada of CTA for PGN-EDO51

PepGen Logo

PepGen has received clearance by Health Canada for the CONNECT1-EDO51 Phase 2 clinical trial of PNG-EDO51, an exon 51 skipping therapy.

Continue reading

Sarepta Therapeutics: Positive Vote from U.S. FDA for SRP-9001

Sarepta Therapeutics Logo

The first-ever FDA Advisory Committee meeting for a gene therapy intended to treat Duchenne muscular dystrophy received a positive vote for accelerated approval of SRP-9001.

Continue reading

Santhera and ReveraGen: Vamorolone NDA Mid-Cycle Review with FDA

Santhera & ReveraGen Logo

Santhera has shared it’s launch plans for vamorolone in the US, EU, and UK, as well as an update on the FDA mid-cycle review.

Continue reading

Avidity Biosciences: Granted FDA Fast Track Designation for AOC 1044

Avidity Biosciences - Logo

Avidity Biosciences has been granted Fast Track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) in people with mutations amenable to exon 44 skipping (DMD44) by the FDA in the United States.

Continue reading

NS Pharma: FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02

NS Pharma Logo

NS Pharma has received FDA clearance to initiate a Phase II Study for NS-089/NCNP-02, an exon 44 skipping candidate for Duchenne muscular dystrophy.

Continue reading

REGENXBIO: FDA Fast Track Designation for RGX-202

Regenx Bio Logo

REGENXBIO has received FDA fast track designation for RGX-202, their gene therapy candidate for Duchenne muscular dystrophy.

Continue reading

Edgewise Therapeutics: New Publication

Edgewise Therapeutics

Edgewise Therapeutics has published a new article in the Journal of Clinical Investigation discussing EDG-5006, their oral small-molecule muscle stabilizer for Duchenne and Becker muscular dystrophy.

Continue reading

Capricor Therapeutics: Positive 18-Month Results from HOPE-2 Open Label Extension Study of CAP-1002

Capricor Therapeutics Logo

Capricor Therapeutics has presented the 18-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy.

Continue reading

PepGen: Preclinical Data of PGN-EDO51 and Announcement of CONNECT1-EDO51 Canadian Clinical Trial

PepGen Logo

PepGen has presented clinical and nonclinical data at the 2023 Annual Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, including an update on a Canadian clinical trial for Duchenne.

Continue reading

Dyne Therapeutics: FDA Orphan Drug and Rare Pediatric Designations for DYNE-251

Dyne Therapeutics Logo

Dyne Therapeutics has received FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the treatment of Duchenne muscular dystrophy.

Continue reading
  • 1
  • 2
  • 3
  • ...
  • 27
  • Next

Sign up to receive our e-news

Get the latest news on Duchenne research, events, support & education, and ways you can help to defeat Duchenne.

All fields are mandatory.

Defeat Duchenne Canada
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • Annual Reports
  • FR
×
  • For Researchers
  • For Healthcare Professionals
  • Contact Us
  • Annual Reports
  • FR

Mailing Address
PO Box 51, Station B
London, ON N6A 4V3

+1-519-645-8855

info@defeatduchenne.ca

Donate Now
The Jesse Davidson Foundation
Charitable Number: 89509-7756-RR0001
Facebook-f Twitter Instagram Youtube Linkedin

© 2023 Defeat Duchenne Canada. All rights reserved.

  • Privacy Policy